Why was Carrie S escorted out of the building?

Quote

















AGN failed to pivot when needed several years ago. Now they’ll milk the exorbitant pricing till consumers realize other “me too” products work just as well.

Was a good run.
 


anonymous said:
AGN failed to pivot when needed several years ago. Now they’ll milk the exorbitant pricing till consumers realize other “me too” products work just as well.

Was a good run.
Click to expand...
“Me too” is what this industry is about in the absence of innovation. Toxins are all the same stuff, fillers all the same stuff. The only difference is the price. There hasn’t been anything new or truly innovative in the last 15 years. Allergan will be impacted the most as there are plenty of cheaper options.
 








anonymous said:
But why is it a crowded and tough market. We were there first. We have been investing in R&D and BD before anyone else. Shouldn’t we have new and differentiated products? Why does evolus have a new filler? Why don’t we? Who is making the decisions that got us here? Really.
Click to expand...
Very good point. There is nothing new for long time scientific/technical leadership is very weak and non productive.
 




I wish her much success. She had to deal with a hot mess inherited from Brent’s mgmt and then had to integrate it with another hot mess that was Abbvie. Not to mention the culture clash and how Abbvie struggles with the aesthetic industry.
 


anonymous said:
I wish her much success. She had to deal with a hot mess inherited from Brent’s mgmt and then had to integrate it with another hot mess that was Abbvie. Not to mention the culture clash and how Abbvie struggles with the aesthetic industry.
Click to expand...
Wonder if Abbie will stay in aesthetics or get rid of the business
 





Write your reply...
Top Bottom
Back
Quote